On June 29, 2021 Takeda Pharmaceutical Company Limited ("Takeda") (TSE:4502/NYSE:TAK) reported that it has filed its Annual Report on Form 20-F for the fiscal year ended March 31, 2021 (the "Annual Report") with the U.S. Securities and Exchange Commission (the "SEC") (Press release, Takeda, JUN 29, 2021, View Source [SID1234584481]). Takeda filed the Annual Report with the SEC on June 29, 2021, and the Annual Report can be accessed on Takeda’s website at: View Source

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In addition, Takeda will also provide a hard copy of the Annual Report, which includes its most recent complete audited financial statements free of charge to any shareholder upon request. Please contact Takeda Investor Relations by e-mail at [email protected].

Additionally, Takeda also published today its 2021 Annual Integrated Report for the fiscal year ended March 31, 2021. It can be accessed on Takeda’s website at: View Source